Literature DB >> 32932221

Preoperative C-reactive protein-to-albumin ratio and clinical outcomes after resection of colorectal liver metastases.

Yuki Sakamoto1, Kosuke Mima2, Katsunori Imai1, Yuji Miyamoto1, Ryuma Tokunaga1, Takahiko Akiyama1, Nobuya Daitoku1, Yukiharu Hiyoshi1, Masaaki Iwatsuki1, Yohei Nagai1, Yoshifumi Baba1, Shiro Iwagami1, Yo-Ichi Yamashita1, Naoya Yoshida1, Hideo Baba3.   

Abstract

PURPOSE: Accumulating evidence suggests that the inflammatory tumor microenvironment can potentiate tumor progression and metastasis. The C-reactive protein-to-albumin ratio (CAR) is a novel inflammation-based prognostic score. This study was performed to examine the associations of the preoperative CAR with clinical outcomes in patients with colorectal liver metastases (CRLM) after curative resection.
METHODS: We retrospectively assessed the preoperative CAR in 184 patients who underwent curative resection for CRLM from November 2001 to January 2018 at Kumamoto University (Kumamoto, Japan). The optimal cutoff level of the preoperative CAR was determined by survival classification and regression tree (CART) analysis. We compared clinicopathological factors and prognoses between the high-CAR and low-CAR groups. A Cox proportional hazards model was used to calculate hazard ratios (HRs), controlling for potential confounders.
RESULTS: A higher preoperative CAR was associated with worse overall survival (OS) (p < 0.0001) and recurrence-free survival (RFS) (p = 0.003). Applying survival CART analysis, the high-CAR group comprised 33 patients (17.9%). In the multivariate analyses, a high CAR was independently associated with shorter OS (HR, 2.82; 95% confidence interval, 1.63-4.72; p = 0.0004) and RFS (HR, 1.62; 95% confidence interval, 1.02-2.49; p = 0.040). A high CAR was associated with a large tumor size, high serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels, high intraoperative blood loss, and more postoperative complications.
CONCLUSION: A high preoperative CAR is associated with shorter OS and RFS and might serve as a prognostic marker for patients with CRLM after curative resection.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  CAR; Colorectal cancer; Liver metastasis

Year:  2020        PMID: 32932221     DOI: 10.1016/j.suronc.2020.09.014

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

1.  Prognostic value of C-reactive protein to albumin ratio in metastatic colorectal cancer: A systematic review and meta-analysis.

Authors:  Yan Pan; Yinmei Lou; Lin Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

2.  C-reactive protein/albumin ratio and Glasgow prognostic score are associated with prognosis and infiltration of Foxp3+ or CD3+ lymphocytes in colorectal liver metastasis.

Authors:  Hiroki Kanno; Toru Hisaka; Jun Akiba; Kazuaki Hashimoto; Fumihiko Fujita; Yoshito Akagi
Journal:  BMC Cancer       Date:  2022-08-01       Impact factor: 4.638

Review 3.  Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis.

Authors:  Chun-Kai Liao; Yen-Lin Yu; Yueh-Chen Lin; Yu-Jen Hsu; Yih-Jong Chern; Jy-Ming Chiang; Jeng-Fu You
Journal:  World J Surg Oncol       Date:  2021-05-01       Impact factor: 2.754

4.  The advanced lung cancer inflammation index is a novel independent prognosticator in colorectal cancer patients after curative resection.

Authors:  Taichi Horino; Ryuma Tokunaga; Yuji Miyamoto; Yukiharu Hiyoshi; Takahiko Akiyama; Nobuya Daitoku; Yuki Sakamoto; Naoya Yoshida; Hideo Baba
Journal:  Ann Gastroenterol Surg       Date:  2021-09-14

5.  Prognostic Value of the C-Reactive Protein/Albumin Ratio and Systemic Immune-Inflammation Index for Patients With Colorectal Liver Metastasis Undergoing Curative Resection.

Authors:  Yuxiang Deng; Yujie Zhao; Jiayi Qin; Xiaozhen Huang; Ruomei Wu; Caixia Zhou; Zhizhong Pan
Journal:  Pathol Oncol Res       Date:  2021-03-24       Impact factor: 3.201

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.